Implantica AG (IMP-A-SDB.ST)
SEK 26.0
(-2.07%)
SEK 26.0
(-2.07%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -21.77 Million EUR | -18.42% |
| 2022 | -18.38 Million EUR | -40.36% |
| 2021 | -13.09 Million EUR | -23.53% |
| 2020 | -10.6 Million EUR | -133.67% |
| 2019 | -4.53 Million EUR | 10.17% |
| 2018 | -5.05 Million EUR | -30.99% |
| 2017 | -3.85 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -5.77 Million EUR | 17.37% |
| 2024 Q1 | -6.98 Million EUR | -2.17% |
| 2023 Q1 | -4.77 Million EUR | 4.65% |
| 2023 FY | - EUR | -18.42% |
| 2023 Q4 | -6.83 Million EUR | -20.97% |
| 2023 Q3 | -5.65 Million EUR | -35.19% |
| 2023 Q2 | -4.17 Million EUR | 12.48% |
| 2022 Q4 | -5 Million EUR | -12.44% |
| 2022 Q3 | -4.45 Million EUR | -5.37% |
| 2022 Q2 | -4.22 Million EUR | 1.51% |
| 2022 FY | - EUR | -40.36% |
| 2022 Q1 | -4.29 Million EUR | -8.82% |
| 2021 Q3 | -3.85 Million EUR | -31.99% |
| 2021 Q2 | -2.92 Million EUR | -31.08% |
| 2021 Q1 | -2.23 Million EUR | 32.36% |
| 2021 Q4 | -3.94 Million EUR | -2.26% |
| 2021 FY | - EUR | -23.53% |
| 2020 FY | - EUR | -133.67% |
| 2020 Q2 | -1.03 Million EUR | 23.95% |
| 2020 Q4 | -3.29 Million EUR | 30.3% |
| 2020 Q3 | -4.73 Million EUR | -357.01% |
| 2020 Q1 | -1.36 Million EUR | -26.96% |
| 2019 Q3 | -699.33 Thousand EUR | 0.0% |
| 2019 Q4 | -1.07 Million EUR | -53.29% |
| 2019 FY | - EUR | 10.17% |
| 2018 FY | - EUR | -30.99% |
| 2017 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 71.769% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 105.286% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 105.286% |
| Arcoma AB | 6.24 Million SEK | 448.464% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 75.804% |
| BICO Group AB (publ) | 322.3 Million SEK | 106.755% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 132.998% |
| CellaVision AB (publ) | 207.24 Million SEK | 110.505% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 68.172% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 22.084% |
| C-Rad AB (publ) | 48.9 Million SEK | 144.52% |
| Duearity AB (publ) | -24.77 Million SEK | 12.135% |
| Dignitana AB (publ) | -264 Thousand SEK | -8146.97% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 75.174% |
| Getinge AB (publ) | 5.92 Billion SEK | 100.367% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 67.625% |
| Iconovo AB (publ) | -35.33 Million SEK | 38.385% |
| Integrum AB (publ) | 8.76 Million SEK | 348.495% |
| Luxbright AB (publ) | -23.86 Million SEK | 8.777% |
| Mentice AB (publ) | 28.87 Million SEK | 175.406% |
| OssDsign AB (publ) | -122.02 Million SEK | 82.157% |
| Paxman AB (publ) | 31.22 Million SEK | 169.717% |
| Promimic AB (publ) | -3.68 Million SEK | -490.988% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 85.534% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 57.993% |
| ScandiDos AB (publ) | -13.35 Million SEK | -63.013% |
| Sectra AB (publ) | 615.06 Million SEK | 103.54% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 57.867% |
| Senzime AB (publ) | -118.82 Million SEK | 81.677% |
| SpectraCure AB (publ) | -20.96 Million SEK | -3.829% |
| Stille AB | 56.04 Million SEK | 138.85% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 99.316% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 117.201% |